Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: GART

Gene summary for GART

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

GART

Gene ID

2618

Gene namephosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase
Gene AliasAIRS
Cytomap21q22.11
Gene Typeprotein-coding
GO ID

GO:0003360

UniProtAcc

P22102


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
2618GARTHTA11_99999970781_79442HumanColorectumMSS1.70e-096.39e-010.294
2618GARTHTA11_99999965062_69753HumanColorectumMSI-H2.79e-041.10e+000.3487
2618GARTHTA11_99999965104_69814HumanColorectumMSS5.39e-077.51e-010.281
2618GARTHTA11_99999971662_82457HumanColorectumMSS9.06e-055.87e-010.3859
2618GARTA015-C-203HumanColorectumFAP2.34e-08-2.14e-01-0.1294
2618GARTA015-C-204HumanColorectumFAP1.52e-03-2.37e-01-0.0228
2618GARTA002-C-201HumanColorectumFAP9.32e-07-1.84e-010.0324
2618GARTA001-C-119HumanColorectumFAP3.41e-03-2.46e-01-0.1557
2618GARTA001-C-108HumanColorectumFAP1.18e-03-7.50e-02-0.0272
2618GARTA002-C-205HumanColorectumFAP5.21e-09-1.05e-01-0.1236
2618GARTA015-C-006HumanColorectumFAP1.66e-06-1.58e-01-0.0994
2618GARTA015-C-106HumanColorectumFAP2.69e-02-1.23e-01-0.0511
2618GARTA002-C-114HumanColorectumFAP7.42e-08-2.27e-01-0.1561
2618GARTA015-C-104HumanColorectumFAP2.21e-10-2.28e-01-0.1899
2618GARTA002-C-016HumanColorectumFAP5.82e-09-2.06e-010.0521
2618GARTA015-C-002HumanColorectumFAP2.05e-06-3.09e-01-0.0763
2618GARTA002-C-116HumanColorectumFAP5.72e-11-1.83e-01-0.0452
2618GARTA014-C-008HumanColorectumFAP8.97e-05-5.24e-02-0.191
2618GARTA018-E-020HumanColorectumFAP1.74e-09-2.50e-01-0.2034
2618GARTF034HumanColorectumFAP6.40e-06-1.15e-01-0.0665
Page: 1 2 3 4 5 6 7 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:000912614ThyroidPTCpurine nucleoside monophosphate metabolic process25/596844/187235.43e-043.48e-0325
GO:007252219ThyroidPTCpurine-containing compound biosynthetic process86/5968200/187235.85e-043.72e-0386
GO:000916710ThyroidPTCpurine ribonucleoside monophosphate metabolic process23/596841/187231.14e-036.65e-0323
GO:004239813ThyroidPTCcellular modified amino acid biosynthetic process25/596846/187231.31e-037.43e-0325
GO:000616419ThyroidPTCpurine nucleotide biosynthetic process81/5968191/187231.35e-037.65e-0381
GO:00215438ThyroidPTCpallium development72/5968169/187232.09e-031.11e-0272
GO:00091135ThyroidPTCpurine nucleobase biosynthetic process8/596810/187232.46e-031.27e-028
GO:00215373ThyroidPTCtelencephalon development100/5968248/187232.90e-031.44e-02100
GO:002198713ThyroidPTCcerebral cortex development50/5968114/187234.71e-032.21e-0250
GO:00091236ThyroidPTCnucleoside monophosphate metabolic process35/596876/187236.68e-032.89e-0235
GO:00309007ThyroidPTCforebrain development143/5968379/187238.47e-033.56e-02143
GO:001969328ThyroidATCribose phosphate metabolic process184/6293396/187235.87e-081.05e-06184
GO:000915029ThyroidATCpurine ribonucleotide metabolic process172/6293368/187239.58e-081.64e-06172
GO:000925928ThyroidATCribonucleotide metabolic process178/6293385/187231.47e-072.39e-06178
GO:007252128ThyroidATCpurine-containing compound metabolic process189/6293416/187232.83e-074.29e-06189
GO:0006753111ThyroidATCnucleoside phosphate metabolic process219/6293497/187235.92e-078.29e-06219
GO:0009117112ThyroidATCnucleotide metabolic process215/6293489/187239.09e-071.20e-05215
GO:000616328ThyroidATCpurine nucleotide metabolic process177/6293396/187232.39e-062.82e-05177
GO:000915225ThyroidATCpurine ribonucleotide biosynthetic process84/6293169/187231.05e-051.04e-0484
GO:004639025ThyroidATCribose phosphate biosynthetic process92/6293190/187231.57e-051.46e-0492
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa00670ColorectumMSI-HOne carbon pool by folate7/79720/84651.65e-031.73e-021.45e-027
hsa006701ColorectumMSI-HOne carbon pool by folate7/79720/84651.65e-031.73e-021.45e-027
hsa015232EsophagusESCCAntifolate resistance22/420530/84657.23e-031.76e-028.99e-0322
hsa0152311EsophagusESCCAntifolate resistance22/420530/84657.23e-031.76e-028.99e-0322
hsa006702LiverHCCOne carbon pool by folate17/402020/84656.04e-042.50e-031.39e-0317
hsa01523LiverHCCAntifolate resistance21/402030/84651.06e-022.71e-021.51e-0221
hsa0067011LiverHCCOne carbon pool by folate17/402020/84656.04e-042.50e-031.39e-0317
hsa015231LiverHCCAntifolate resistance21/402030/84651.06e-022.71e-021.51e-0221
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
GARTSNVMissense_Mutationnovelc.2695N>Ap.Leu899Ilep.L899IP22102protein_codingtolerated(0.07)probably_damaging(0.987)TCGA-AN-A046-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
GARTSNVMissense_Mutationc.667G>Cp.Glu223Glnp.E223QP22102protein_codingdeleterious(0.01)benign(0.179)TCGA-BH-A1FC-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
GARTSNVMissense_Mutationc.1193N>Tp.Ser398Leup.S398LP22102protein_codingtolerated(0.39)benign(0.011)TCGA-C8-A26Y-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
GARTSNVMissense_Mutationc.342N>Ap.Met114Ilep.M114IP22102protein_codingdeleterious(0)probably_damaging(0.959)TCGA-C8-A26Y-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
GARTinsertionIn_Frame_Insnovelc.1301_1302insCATACATATCCTp.Ser434_Leu435insIleHisIleLeup.S434_L435insIHILP22102protein_codingTCGA-AR-A0U0-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
GARTdeletionFrame_Shift_Delc.3002delAp.Asn1001MetfsTer14p.N1001Mfs*14P22102protein_codingTCGA-BH-A18G-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
GARTdeletionFrame_Shift_Delrs777845343c.2420delAp.Lys807ArgfsTer7p.K807Rfs*7P22102protein_codingTCGA-D8-A1XK-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapydoxorubicine+cyclophosphamideSD
GARTSNVMissense_Mutationc.1237G>Ap.Glu413Lysp.E413KP22102protein_codingtolerated(0.33)benign(0.012)TCGA-C5-A8XJ-01Cervixcervical & endocervical cancerFemale>=65I/IIChemotherapycisplatinSD
GARTSNVMissense_Mutationc.2488N>Cp.Glu830Glnp.E830QP22102protein_codingtolerated(0.26)benign(0.006)TCGA-JW-A852-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownPD
GARTSNVMissense_Mutationc.763N>Ap.Leu255Ilep.L255IP22102protein_codingtolerated(0.1)probably_damaging(0.947)TCGA-AA-A010-01Colorectumcolon adenocarcinomaFemale<65I/IIChemotherapyfolinicCR
Page: 1 2 3 4 5 6 7 8 9 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
2618GARTENZYME, DRUGGABLE GENOMEinhibitorCHEMBL1200373
2618GARTENZYME, DRUGGABLE GENOMEPEMETREXEDPEMETREXED
2618GARTENZYME, DRUGGABLE GENOMEPELITREXOLPELITREXOL
2618GARTENZYME, DRUGGABLE GENOMELY309887
2618GARTENZYME, DRUGGABLE GENOMEPEMETREXEDPEMETREXED
2618GARTENZYME, DRUGGABLE GENOMEAG2034
2618GARTENZYME, DRUGGABLE GENOMELOMETREXOLLOMETREXOL22243528
Page: 1